Chitosan–HPMC-blended microspheres as a vaccine carrier for the delivery of tetanus toxoid

References

• Alpar HO, Almeida AJ, Brown MRW, Williamson ED. 1994. Immune responses to mucosally administered tetanus toxoid in biodegradable PLA microspheres. Proc Int Cont Rel Bioact Mater. 21:867–868.
   Google Scholar
• Arthanari S, Renukadevi P, Mani KR. 2011. Preparation and evaluation of sucrose stabilized tetanus toxoid encapsulated into chitosan microspheres. Gen Med Biomark Health Sci. 3:91–97.
   Google Scholar
• Arthanari S, Renukadevi P, Saravanakumar V. 2014. Evaluation of lactose stabilized tetanus toxoid encapsulated into alginate, HPMC composite microspheres. J Ind Eng Chem. 20:2018–2022.
   Web of Science ®Google Scholar
• Barman SP, Lunsford L, Chambers P, Hedley ML. 2000. Two methods for quantifying DNA extracted from poly (lactide-co-glycolide) microspheres. J Control Release. 69:337–344.
   PubMed Web of Science ®Google Scholar
• Bilati U, Allemann E, Doelker E. 2005. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur J Pharm Biopharm. 59:375–388.
   PubMed Web of Science ®Google Scholar
• Cleland JL, Barron L, Berman PW, Daugherty A, Gregory T, Lim A. 1996. Development of a single shot sub unit vaccine for HIV-1 and 2. Defining optimal auto boost characteristics the humoral immune response. J Pharm Sci. 85:1346–1349.
   PubMed Web of Science ®Google Scholar
• Cleland JL, Jones AJS. 1996. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm Res. 13:1464–1475.
   PubMed Web of Science ®Google Scholar
• Cox JC, Coulter AR. 1997. Adjuvants – a classification and review of their modes of action. Vaccine. 15:248–256.
   PubMed Web of Science ®Google Scholar
• Derek T, O’Hagan DT, Rappuoli R. 2004. Novel approaches to vaccine delivery. Pharma Res. 21:1519–1530.
   Google Scholar
• Eldridge JH, Gilley RM, Staas JK, Moldoveanu A, Merlbroek JA, Tice TR. 1989. Biodegradable microspheres: a vaccine delivery system for oral immunization. Curr Top Microbial Immun. 146:59–66.
   PubMed Web of Science ®Google Scholar
• Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. 1991. Biodegradable and biocompatible poly (dl-lactide co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun. 59:2978–2986.
   PubMed Web of Science ®Google Scholar
• Felt O, Buri P, Gurny R. 1998. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm. 24:979–993.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Siber GR. 1995. Adjuvants for human vaccines – current status, problems and future prospects. Vaccine. 13:1263–1276.
   PubMed Web of Science ®Google Scholar
• Hirrien M, Chevillard C, Desbrieres J, Axelos MAV, Rinaudo M. 1998. Thermogelation of methylcelluloses. New evidence for understanding the gelation mechanism. Polymer. 39:6251–6259.
   Web of Science ®Google Scholar
• Hirrien M, Chevillard C, Desbrieres J, Axelos MAV, Rinaudo M. 1996. Physical properties of methylcelluloses in relation with the conditions for cellulose modification. Carbohyd Poly. 31:243–252.
   Web of Science ®Google Scholar
• Ibbett RN, Philp K, Price DM. 1992. 13C n.m.r. studies of the thermal behaviour of aqueous solutions of cellulose ethers. Polymer. 19:4087–4094.
   Google Scholar
• Illum L. 1998. Chitosan and its use as a pharmaceutical excipient. Pharm Res. 15:1326–1331.
   PubMed Web of Science ®Google Scholar
• Indian Pharmacopoeia. 1985. Ministry of Health and Family Welfare. Government of India, 2: A39.
   Google Scholar
• Jaganathan KS, Rao YUB, Singh P, Prabakaran D, Gupta S, Jain A, Vyas SP. 2005. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly (d,l-lactic-co-glycolic acid) versus chitosan microspheres. Int J Pharm. 294:23–32.
   PubMed Web of Science ®Google Scholar
• Jameela SR, Mishra A, Jayakrishnan A. 1994. Cross-linked chitosan microspheres as carriers for prolonged delivery of macromolecular drugs. J Biomat Sci Polym Edu. 6:621–632.
   PubMed Web of Science ®Google Scholar
• Joane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. 1999. Evaluation of the clearance characteristics of bio adhesive systems in humans. Int J Pharm. 178:55–65.
   PubMedGoogle Scholar
• Johansen P, Men Y, Audran R, Corradin G, Merkle HP, Gander B. 1998. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm Res. 15:1103–1110.
   PubMed Web of Science ®Google Scholar
• Kohn J, Niemi SM, Albert EC, Murphy JC, Langer RS, Fox JG. 1986. Single step immunization using a controlled release, biodegradable polymer with sustained adjuvant activity. J Immunol Met. 95:31–38.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Speiser P. 1976. New adjuvants on a polymethyl methacrylate base. Infect Immun. 13:204.
   PubMed Web of Science ®Google Scholar
• Lutsiak CME, Kwon GS, Samuel J. 2006. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol. 58:739–747.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Jeffery H, Davis SS. 1993. Long term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microspheres. Vaccine. 11:965–969.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rahman D, McGee JP, Jeffery H, Davies MC, Williams P. 1991. Biodegradable microparticles as controlled release antigen delivery system. Immunology. 73:239–242.
   PubMed Web of Science ®Google Scholar
• Oladiran I, Meier DE, Ojelade AA, OlaOlarun DA, Adeniran A, Tarpley JL. 2002. Tetanus: continuing problem in the developing world. World J Surg. 26:1282–1285.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. 2004. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82:482–496.
   Web of Science ®Google Scholar
• Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, et al. 1997. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun. 65:1716–1721.
   PubMed Web of Science ®Google Scholar
• Trujillo Vargas CM, Mayer KD, Bickert T, Palmetshofer A, Grunewald S, Ramirez Pineda JR, et al. 2005. Vaccinations with T helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T helper type 2 responses. Clin Exp Allergy. 35:1003–1013.
   PubMed Web of Science ®Google Scholar
• Vandelaer J, Birmingham M, Gasse F, Kurian M, Shaw C, Garnier S. 2003. Tetanus in developing countries; an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine. 21: 3442–3445.
   PubMed Web of Science ®Google Scholar
• van der Lubben LM, Verhoef JC, Borchard G, Junginger HE. 2001. Chitosan for mucosal vaccination. Adv Drug Deliv Rev. 52:139–144.
   PubMed Web of Science ®Google Scholar
• Warren HS, Vogel FR, Chedid LA. 1986. Current status of immunological adjuvants. Ann Rev Immunol. 4:369–376.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Leong KW. 1996. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci. 85:1261–1270.
   PubMed Web of Science ®Google Scholar